MedMira Granted Hepatitis C Patent in Europe

Patent Further Protects MedMira's Diagnostic Technology

Jan 03, 2006, 00:00 ET from MedMira Inc.

    HALIFAX, Jan. 3 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
 Venture: MIR, NASDAQ:   MMIRF) the global market leader in premium rapid
 diagnostic solutions, announced today that it has been granted a patent for
 the HCV Mosaic Antigen by the European Patent Office. This is the company's
 first major patent on its rapid diagnostic technology in Europe, and paves the
 way for the world's first combination HIV and Hepatitis C instant rapid test.
     Hepatitis C (HCV) impacts over 170 million people worldwide according to
 the World Health Organization, which also indicates over 40% of individuals
 with HIV are co-infected with HCV. A combination rapid HIV/HCV test can play a
 critical role in patient outcomes.
     Patent No. EP 1328 811 B1 will ensure that MedMira's rapid HCV diagnostic
 technology is protected as it is brought to market in Europe. The patented
 technology is a key component in MedMira's rapid HCV tests and HIV/HCV
 combination tests slated for market entry in 2007.
     "We are very pleased to receive this patent for our groundbreaking
 technology," said Hermes Chan, president and COO of MedMira, and principal
 inventor of the HCV Mosaic Antigen. "Considerable R&D efforts were dedicated
 to developing this technology in the past years. Protecting this valuable
 diagnostic solution through the patent process was an important step in
 bringing the complete line of rapid HCV diagnostic products to the European
     The HCV Mosaic Antigen is a highly immunoreactive mosaic antigen
 composition containing a plurality of different antigenic peptides encoded
 from the core region of the HCV genome. The granted patent also describes a
 test kit utilizing the antigen, and a method for its use for the purpose of
 detecting antibodies to HCV in a test sample.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro
 flow-through rapid diagnostic tests. MedMira's tests provide reliable, rapid
 diagnosis in just 3 minutes for the detection of human antibodies in human
 serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
 United States FDA and the SFDA in the People's Republic of China have approved
 MedMira's Reveal(TM) G2 and MiraWell(R) rapid HIV tests, respectively.
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
 in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter
 (OTC) product, is available in pharmacies throughout Hong Kong and Macao
 Special Administrative Regions, in the People's Republic of China.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 Guilin, China.
     This news release contains forward-looking statements, which involve risk
 and uncertainties and reflect the company's current expectation regarding
 future events. Actual events could materially differ from those projected
 herein and depend on a number of factors including, but not limited to,
 changing market conditions, successful and timely completion of clinical
 studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.